Non-Invasive Diagnosis of Abdomino-Pelvic Masses: Role of Multimodality Imaging

Vijayanadh Ojili, Sree Harsha Tirumani¹, Kedar N. Chintapalli, Gowthaman Gunabushanam²
Department of Radiology, University of Texas Health Sciences Centre at San Antonio, San Antonio, TX 78229, ¹Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, ²Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut, 06520-8042, USA

ABSTRACT

Recent advances in radiology have greatly increased the ability to make highly accurate diagnosis. Biopsy of many commonly seen lesions is no longer performed as the radiological findings are pathognomonic. This gives rise to the concept of ‘virtual biopsy’, a term coined on the lines of other imaging techniques such as virtual colonoscopy. Virtual biopsy is not a new imaging technique but a new concept which refers to the use of existing imaging modalities to evaluate the morphological features of tumors and arriving at a non-invasive diagnosis with a high degree of confidence obviating the need for true biopsy. Elements of virtual biopsy have already been incorporated into some evidence-based guidelines, and it is expected that with further technological advancements, an increasing number of tumors may be diagnosed and managed accordingly. A wider acceptance of virtual biopsy could further reduce the need for invasive biopsies and its attendant costs and risks. In this review article, we use index cases to further emphasize this concept.

Key words: Abdomen, computed tomography, magnetic resonance imaging, ultrasound, virtual biopsy

INTRODUCTION

The ultimate goal of radiology is to make an accurate diagnosis noninvasively that reflects the underlying pathological condition. With recent advances in imaging techniques, availability of novel contrast agents and better understanding of the pathophysiological basis of disease processes, radiological diagnoses can be made with such a high degree of accuracy in some conditions that an invasive biopsy is almost never warranted. This has the potential to give rise to the radiological concept of ‘virtual biopsy’. Virtual biopsy, unlike virtual colonoscopy is not a new imaging technique, but a different way of looking at the existing imaging modalities and their diagnostic capabilities. It refers to the use of existing imaging techniques to evaluate the morphological features of tumors and arriving at a non-invasive diagnosis with a high degree of confidence. The key to making such an accurate diagnosis lie in
understanding the correlation between radiological and histomorphological features of tumors. A close attention to the fine details on imaging and prudent use of combination of imaging modalities form the basis for the future of virtual biopsy. Already, evidence-based guidelines such as the Royal College of Radiologists referral guidelines, the American College of Radiology (ACR) appropriateness criteria for adrenal tumors, and the American Association for the Study of Liver Diseases (AASLD) practice guidelines for hepatocellular carcinoma (HCC), incorporate elements of the virtual biopsy concept. Further familiarizing general practitioners and non-radiology specialists with this concept may help avoid unnecessary referrals for biopsy and additional work-up. In this review, we use few illustrative examples to show conditions where a virtual biopsy is possible due to highly accurate radiological diagnosis, thereby obviating the need for an invasive biopsy.

**LIVER**

**Hemangioma**

Hemangioma is the most common benign solid liver lesion and often incidentally detected in asymptomatic women, unless very large in size, when it may cause symptoms due to its size and pressure. Typical hemangioma is seen on ultrasound (US) as a well-defined hyperechoic lesion with posterior acoustic enhancement, while on dynamic computed tomography (CT), it demonstrates peripheral nodular enhancement with progressive centripetal filling. At magnetic resonance (MR) imaging, it typically has low signal on T1-weighted and high signal on T2-weighted sequences, retaining high signal on long TE sequences. It appears bright on diffusion weighted images (DWI) with mean apparent diffusion co-efficient (ADC) values usually between cysts and HCC; however, there can be significant overlap. Enhancement on post gadolinium images is identical to CT, with no uptake of hepatocyte specific agents. Typical hemangiomas are diagnosed with 99% accuracy, 98% sensitivity and specificity and almost never biopsied. The hyperechoic and often heterogeneous appearance of adenomas on US [Figure 1a] is due to their lipid content and hemorrhage.\(^{[3]}\) Doppler US may show peripheral and intratumoral vessels with low resistance flow reflecting their hepatic arterial supply.\(^{[3]}\) Unenhanced CT demonstrates an iso-, or less commonly hypo- or hyper-attenuating lesion relative to the liver parenchyma depending on lipid content and hemorrhage. Dynamic CT shows hypervascular lesion in the hepatic arterial phase which is iso-attenuating in the venous phase [Figure 1b and c].\(^{[6]}\) CT also demonstrates complications such as hemorrhage and rupture [Figure 1d]. At MR, adenoma may be hypo-, iso- or hyperintense on T1-weighted images and predominantly high signal on T2-weighted images.\(^{[3]}\) High T1-weighted signal seen in 35% of adenomas may be due to lipid or hemorrhage.\(^{[3]}\) Delayed phase imaging shows no enhancement with Gd-BOPTA but variable enhancement with Gd-EOB-DTPA.\(^{[4,5]}\)

**Focal nodular hyperplasia**

Focal nodular hyperplasia (FNH) is the second most common benign liver tumor. It is more common in women and develops as a hyperplastic reaction to vascular malformations. Classic FNH is characterized by abnormal nodular architecture, cholangiolar proliferation and malformed vessels whereas the non-classic type lacks either the nodular architecture or malformed vessels but always contain biliary channels.\(^{[6]}\) The presence of biliary channels which are dysfunctional is exploited in making a sensitive diagnosis of FNH.

---

**Figure 1:** Multiple hepatic adenomas. (a) Transverse ultrasound image of the left lobe of the liver shows a heterogeneous, predominantly hyperechoic lesion (arrow) with no overlying liver parenchyma. Another hypoechoic lesion (arrow head) is seen anteriorly. (b and c) Axial contrast-enhanced computed tomography (CT) sections of the liver in (b) hepatic arterial and (c) portal venous phases reveal hypervascular lesions (white arrows and arrowhead) in the left lobe of the liver which are isodense on the venous phase. Note the absence of capsule and peripheral liver parenchyma. Small incidental left renal angiomylipomas (double lined arrows in c) are also noted. A diagnosis of multiple hepatic adenomas was made. (d) Axial contrast-enhanced CT image demonstrates rupture of the hepatic adenoma (arrow) with peripheric hematoma. The patient was initially managed with hepatic artery embolization and the lesions were subsequently excised surgically with histopathology confirming adenomas.
The imaging hallmark of FNH is their close resemblance to the normal hepatic parenchyma. FNH is often seen as a subtle change in echogenicity compared to surrounding liver parenchyma with a hypoechoic halo of surrounding compressed parenchyma in some cases.[6] On CT (Figure 2), FNH is usually isodense on unenhanced images and hyperdense on the arterial phase, becoming isoattenuating to the surrounding liver in the venous phase. Classic FNH has a central scar which is hypodense and enhances on the delayed phase.[6] On magnetic resonance imaging (MRI), FNH is iso- or hypo-intense on T1 and hyper- or iso-intense on T2-weighted images, shows intense homogenous enhancement on arterial phase, becoming iso-intense on venous phase (Figure 3).[6] The central scar is usually hyper-intense on T2-weighted images and may show enhancement on delayed imaging.[6] FNH shows uptake of hepatocyte specific agents like gadoxetate disodium (Gd-EOB-DTPA) due to presence of functioning hepatocytes and appears iso- or hyper-intense due to trapping of the contrast in the aberrant bile ducts (Figure 3).[7] Sensitivity and specificity for MRI in characterizing FNH is 70% and 98% respectively.[6]

**Hepatocellular carcinoma**

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and usually occurs in the setting of cirrhosis and chronic hepatitis B and C infections. Earlier detection of HCC allows initiation of curative therapy and for this, surveillance in cirrhotic patients is performed with alpha-fetoprotein testing and sonography.[8] Sonographic features of HCC are variable with sensitivity as low as 20.5%[9] to as high as 81%.[10] Dynamic CT demonstrates HCC as a hypervascular lesion with abnormal intra-tumoral vessels in the arterial phase, which becomes iso-hypoattenuating on the venous phase images due to washout.[11]

At MRI, HCC is usually hypointense on T1-weighted and intermediate to high signal on T2-weighted images (Figure 4). Small (<2 cm) HCC can be isoointense on both T1 and T2-weighted images.[12] Dynamic gadolinium-enhancement shows hyper-vascular lesion in the arterial phase with washout in the venous phase and enhancing capsule in the delayed phase (Figure 4).[12] The predominant arterial supply of HCC in contrast to the predominant portal venous supply of normal hepatic parenchyma allows prompt detection of hyper-vascular HCC and underscores the need for good arterial phase imaging. Washout in the venous phase helps in differentiating HCC from dysplastic nodule and has sensitivity and specificity of 89% and 96% respectively.[12] At DWI, HCC shows restriction of diffusion with low ADC values.[13] HCC shows variable uptake of hepatocyte specific contrast agents depending on the degree of differentiation.[14] Portal vein thrombus that shows neovasularity and appears hyperintense on T2-weighted images and shows enhancement on dynamic imaging suggests tumor thrombus rather than bland thrombus.[12] Pooled sensitivity and specificity of MRI for HCC detection are 81% and 85% compared to 68% and 93% contrast enhanced spiral CT.[12] Double contrast MR imaging with gadolinium-based and iron oxide particles has sensitivity of 92% for detecting HCC of 1-2 cm size.[12] According to the AASLD practice guidelines, for a lesion >2 cm in a cirrhotic liver, biopsy is not essential if there are typical imaging features in one dynamic imaging study and for lesions between 1 cm and 2 cm, biopsy is not essential if
there are typical imaging features on two dynamic imaging studies.[15]

**RENAL TUMORS**

**Renal cell carcinoma**

Renal cell carcinoma (RCC) is the most common primary malignancy of the kidney and commonly affects men in their fifth to seventh decades. Three major types of RCC which differ in clinical behavior and treatment response include clear cell (80%), papillary (15%) and chromophobe (5%).[16] Clear cell carcinoma is composed of large uniform cells with abundant clear cytoplasm rich in glycogen and lipid.[17]

Clear cell RCC on sonography appears as a hypoechoic or complex solid cystic mass with thick septations. On CT, clear cell variant, owing to its hypervascularity, has the highest attenuation and enhancement in the corticomedullary and nephrographic phases distinguishing it from other types.[17,18] It is hypointense on T1-weighted MR images and iso-hyperintense on T2-weighted images with greater percentage enhancement than other phenotypes on dynamic contrast enhanced MRI [Figure 5]. The presence of lipid-rich cells is taken advantage of by using chemical shift imaging. The intra-tumoral lipid vacuoles result in a characteristic signal drop on opposed-phase MR images, which has a sensitivity of 42-84% and specificity of 94-100% [Figure 5].[16]

**Renal angiomyolipoma**

Renal angiomyolipoma (Renal AML) is a hamartomatous mesenchymal tumor with 80% occurring as isolated sporadic cases and 20% in association with tuberous sclerosis.[19] AML is typically seen as a well-defined hyperechoic mass on US and as a noncalcified cortical tumor with macroscopic fat on CT [Figure 6].[19] At MRI, it has high signal on T1-weighted images with loss of signal on fat-suppressed sequences and variable signal on T2-weighted images due to intra-tumoral soft-tissue, which indicates vascular and smooth muscle components and hemorrhage.[19]

**Adrenal tumors**

Evidence based approach to adrenal lesions resulted in the development of various criteria to make a confident diagnosis of adrenal lesions. ACR appropriateness criteria recommend biopsy only after a lesion is indeterminate on all imaging modalities.[20] Unenhanced CT attenuation of less than 10 HU, presence of intra-voxel lipid, adrenal to spleen signal intensity ratio of less than 0.71 and adrenal signal intensity index of 16.5% on MRI are virtually diagnostic of lipid rich adenoma [Figure 7].[21] On dynamic contrast enhanced CT, an absolute washout of more than 60% or relative washout of more than 40% on 15 min delayed scans are diagnostic of lipid poor adenomas.[21] An absolute enhancement of more than 110-120 HU is diagnostic of pheochromocytoma regardless of washout.[22] Presence of macroscopic fat is diagnostic of myelolipoma [Figure 8].

**UTERUS AND OVARIAS**

Lipoleiomyomas are unusual types of leiomyomas resulting from fatty metamorphosis of smooth muscle cells of leiomyomas, with a reported incidence of 0.03-0.2%.[23] Histologically, they are composed of abundant fat within the myomatous tissue. US shows
Ojili, et al.: Non-invasive diagnosis of abdomino-pelvic masses: Role of multimodality imaging

A predominantly hyperechoic myometrial mass with peripheral hypoechoic rind in contrast to non-degenerated fibroids, which are hypoechoic [Figure 9a]. CT demonstrates a well-circumscribed myometrial lesion with macroscopic fat [Figure 9b]. On MR, the fat component has high signal on T1-weighted images that is suppressed on fat saturated sequences.

Some ovarian tumors have typical imaging features that allow for a highly specific diagnosis to be made. Ovarian teratoma, the most common germ cell tumor of the ovary, has several histological types based on the degree of differentiation. Mature teratoma is composed of tissues derived from two or more germ cell layers. Pathologically, it is a unilocular (88%) cystic lesion composed of sebaceous material and squamous epithelial lining with a raised nodule (Rokitansky nodule) and various other structures like hair follicles, cutaneous glands and muscle. Mature teratoma is seen on sonography as a cystic lesion with echogenic tubercle, diffusely echogenic mass or cystic lesion with echogenic septa. At CT, presence of fat attenuation in an adnexal cyst with or without calcification and fluid level is diagnostic [Figure 10]. The sebaceous component of teratoma has high signal on T1-weighted images matching retroperitoneal fat and variable signal on T2-weighted images with marked signal loss on fat saturated images [Figure 11].
Ovarian teratoma. Axial non-fat-suppressed (a) pre- and (b) fat-suppressed post-gadolinium T1-weighted magnetic resonance images demonstrate high signal intensity areas in the lesion (a) on non-fat-suppressed image which are suppressed on the fat-suppressed image suggestive of macroscopic fat in the lesion (black arrow). Note the presence of a smaller teratoma in the left ovary which shows similar signal characteristics (white arrow).

Figure 12: Retroperitoneal liposarcoma. Coronal reformatted image of contrast-enhanced computed tomography demonstrates a large retroperitoneal mass with areas of fatty attenuation (single arrow) and heterogeneous soft tissue component (asterisk).

MISCELLANEOUS

Lipomas are benign fat containing tumors where as well differentiated liposarcomas are uncommon malignant fat containing tumors. Lipomas can be treated by simple enucleation whereas liposarcomas need wide local excision and long follow up due to high risk of recurrence and dedifferentiation. Simple lipomas do not pose a significant diagnostic dilemma; they appear as encapsulated homogenous fat attenuation lesions on CT and bright T1-weighted and intermediate signal T2-weighted lesions on MRI with occasional smooth septa. These findings are 100% specific for diagnosis of simple lipomas. Well differentiated liposarcomas are characterized by the presence of thick, irregular septa, nodular and/or globular regions of non-adipose tissue within the lesion, total amount of non-adipose tissue composing more than 25% of the lesion and prominent areas of enhancement on both CT and MRI [Figure 12]. In one study, these findings were 100% sensitive and 83% specific for diagnosis of well differentiated liposarcomas.

CONCLUSION

In conclusion, a clear understanding and correlation of the histopathologic and imaging features of certain tumors can help in avoiding an invasive biopsy. Occasionally, a combination of imaging modalities may be required to achieve greater diagnostic certainty. We believe that with further advancements in radiology hardware and the development of tissue specific contrast agents, an increased number of pathological entities may be diagnosed by virtual biopsy. Finally, a greater emphasis on evidence based guidelines could result in the development of more imaging workup algorithms, potentially strengthening the idea of virtual biopsy.

REFERENCES

1. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: Prospective study in 66 patients. Radiology 2003;226:71-8.
2. Maniam S, Szklaruk J. Magnetic resonance imaging: Review of imaging techniques and overview of liver imaging. World J Radiol 2010;2:309-22.
3. Kamaya A, Maturess KE, Tye GA, Liu YJ, Parti NN, Desser TS. Hypervascular liver lesions. Semin Ultrasound CT MR 2009;30:387-407.
4. Grazioi L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: Prospective study. Radiology 2005;236:166-77.
5. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: Part I, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010;195:13-28.
6. van den Bos IC, Hussain SM, de Man RA, Zondervan PE, Ijzermans JN, Krestin GP. Primary hepatic lesions: Imaging findings on state-of-the-art magnetic resonance imaging, with pathologic correlation. Curr Probl Diagn Radiol 2008;37:104-14.
7. Grazioi L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, et al. Hepatocellular adenoma and focal nodular hyperplasia: Value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012;262:520-9.
8. Aghoram R, Cai P, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;9:CD002799.
9. Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman L. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: Correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 2002;179:75-80.
10. Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: Comparison of CT and sonography in 36 liver transplantation patients. AJR Am J Roentgenol 1999;183:303-6.
11. Furlan A, Marin D, Vanzulli A, Patera GP, Ronzon A, Midiri M, et al. Hepatocellular carcinoma in cirrhotic patients at multidetector CT: Hepatic venous phase versus delayed phase for the detection of tumour washout. Br J Radiol 2011;84:403-12.
12. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: Challenges and controversies. Radiology 2008;247:311-30.
13. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254:47-66.
14. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: Role in imaging the liver and biliary tree. Radiographics 2009;29:1725-48.
15. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
16. Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 2009;115:2334-45.
17. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: Diagnosis, staging, and surveillance. AJR Am J Roentgenol 2008;191:1220-32.
18. Jung SC, Cho JY, Kim SH. Subtype differentiation of small renal cell carcinomas on three-phase MDCT: Usefulness of the measurement of degree and heterogeneity of enhancement. Acta Radiol 2012;53:112-8.
18. Umeoka S, Koyama T, Miki Y, Akai M, Tsutsui K, Togashi K. Pictorial review of tuberous sclerosis in various organs. RadioGraphics 2008;28:e32.
20. Choyke PL, ACR Committee on Appropriateness Criteria. ACR Appropriateness Criteria on incidentally discovered adrenal mass. J Am Coll Radiol 2006;3:498-504.
21. Boland GW. Adrenal imaging: Why, when, what, and how? Part 2. What technique? AJR Am J Roentgenol 2011;196:W1-5.
22. Blake MA, Kalra MK, Sweeney AT, Lacey BC, Maher MM, Sahani DV, et al. Distinguishing benign from malignant adrenal masses: Multi-detector row CT protocol with 10-minute delay. Radiology 2006;238:578-85.
23. Kitajima K, Kaji Y, Imanaka K, Sugihara R, Sugimura K. MRI findings of uterine lipoleiomyoma correlated with pathologic findings. AJR Am J Roentgenol 2007;189:W100-4.
24. Loffroy R, Nezal N, Mejean N, Sagot P, Krause D. Lipoleiomyoma of the uterus: Imaging features. Gynecol Obstet Invest 2008;66:73-5.
25. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huetttner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. RadioGraphics 2011;31:625-46.
26. Gaskin CM, Helms CA. Lipomas, lipoma variants, and well-differentiated liposarcomas (atypical lipomas): Results of MRI evaluations of 126 consecutive fatty masses. AJR Am J Roentgenol 2004;182:733-9.
27. Rajiah P, Sinha R, Cuebas C, Dubinsky TJ, Bush WH Jr, Kolokythas O. Imaging of uncommon retroperitoneal masses. RadioGraphics 2011;31:949-76.
28. Chhabra A, Soldatos T. Soft-tissue lesions: When can we exclude sarcoma? AJR Am J Roentgenol 2012;199:1345-57.

Source of Support: Nil, Conflict of Interest: None declared.